Janux Therapeutics, Inc. (NASDAQ:JANX) Receives Consensus Recommendation of “Buy” from Analysts

Janux Therapeutics, Inc. (NASDAQ:JANX) has been given a consensus rating of “Buy” by the twelve research firms that are presently covering the stock, Marketbeat reports. One investment analyst has rated the stock with a hold rating, nine have issued a buy rating and two have assigned a strong buy rating to the company. The average 1-year price target among analysts that have issued ratings on the stock in the last year is $92.44.

Several equities research analysts have recently issued reports on JANX shares. Lifesci Capital raised Janux Therapeutics to a “strong-buy” rating in a research report on Friday, December 27th. Stifel Nicolaus raised their price objective on shares of Janux Therapeutics from $70.00 to $115.00 and gave the stock a “buy” rating in a report on Tuesday, December 3rd. Leerink Partners lifted their price objective on shares of Janux Therapeutics from $79.00 to $91.00 and gave the stock an “outperform” rating in a research report on Tuesday, December 3rd. HC Wainwright reissued a “buy” rating and set a $70.00 target price on shares of Janux Therapeutics in a research report on Monday, March 3rd. Finally, Wedbush reaffirmed an “outperform” rating and issued a $76.00 price target (up previously from $75.00) on shares of Janux Therapeutics in a report on Friday, February 28th.

Janux Therapeutics Stock Performance

Janux Therapeutics stock opened at $29.10 on Monday. The stock has a market cap of $1.72 billion, a PE ratio of -24.87 and a beta of 3.23. Janux Therapeutics has a fifty-two week low of $28.91 and a fifty-two week high of $71.71. The firm’s 50-day simple moving average is $35.60 and its 200 day simple moving average is $46.01.

Janux Therapeutics (NASDAQ:JANX) last released its earnings results on Thursday, February 27th. The company reported ($0.36) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.49) by $0.13. Janux Therapeutics had a negative return on equity of 10.47% and a negative net margin of 463.91%. As a group, analysts predict that Janux Therapeutics will post -1.38 EPS for the current fiscal year.

Insider Activity at Janux Therapeutics

In other news, insider Andrew Hollman Meyer sold 13,334 shares of the stock in a transaction dated Thursday, January 2nd. The shares were sold at an average price of $54.88, for a total value of $731,769.92. Following the sale, the insider now directly owns 82,139 shares of the company’s stock, valued at approximately $4,507,788.32. This represents a 13.97 % decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which can be accessed through the SEC website. Also, Director Ra Capital Management, L.P. acquired 341,742 shares of the business’s stock in a transaction dated Wednesday, March 5th. The stock was purchased at an average price of $30.64 per share, with a total value of $10,470,974.88. Following the completion of the transaction, the director now directly owns 9,658,988 shares of the company’s stock, valued at $295,951,392.32. This trade represents a 3.67 % increase in their position. The disclosure for this purchase can be found here. In the last ninety days, insiders sold 25,002 shares of company stock worth $1,279,953. Corporate insiders own 29.40% of the company’s stock.

Institutional Inflows and Outflows

Several institutional investors have recently made changes to their positions in JANX. Russell Investments Group Ltd. grew its position in Janux Therapeutics by 77.7% during the fourth quarter. Russell Investments Group Ltd. now owns 1,011 shares of the company’s stock worth $54,000 after buying an additional 442 shares in the last quarter. GF Fund Management CO. LTD. bought a new stake in shares of Janux Therapeutics during the 4th quarter valued at about $59,000. Avanza Fonder AB purchased a new position in shares of Janux Therapeutics during the fourth quarter worth about $139,000. Meeder Asset Management Inc. bought a new position in shares of Janux Therapeutics in the fourth quarter worth approximately $159,000. Finally, Tower Research Capital LLC TRC raised its stake in Janux Therapeutics by 878.8% in the fourth quarter. Tower Research Capital LLC TRC now owns 3,827 shares of the company’s stock valued at $205,000 after purchasing an additional 3,436 shares in the last quarter. Institutional investors own 75.39% of the company’s stock.

About Janux Therapeutics

Janux Therapeutics, Inc, a clinical stage biopharmaceutical company, develops immunotherapies based on Tumor Activated T Cell Engagers (TRACTr) and Tumor Activated Immunomodulators (TRACIr) platforms technology to treat patients suffering from cancer. The company's clinical candidates comprise JANX007, a prostate-specific membrane antigen or PSMA-TRACTr, which is in Phase 1 clinical trial in adults for the treatment of metastatic castration-resistant prostate cancer (mCRPC) and the vasculature of other tumors; and JANX008, an epidermal growth factor receptor or EGFR-TRACTr that is in Phase 1 clinical trial for the treatment of multiple solid cancers, including colorectal cancer, squamous cell carcinoma of the head and neck, non-small cell lung cancer, and renal cell carcinoma.